Sanofi Genzyme’s multiple sclerosis therapy Aubagio (teriflunomide) does not appear to cause birth defects in humans as it does in laboratory animals, researchers concluded after studying more than 100 pregnant women with MS.
Their research indicated that birth-defect findings in rats and rabbits do not translate to humans.
The team presented its report, “Pregnancy outcomes in patients with MS treated with teriflunomide: clinical study and post-marketing data,” at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris today. The conference started Oct. 25 and runs through Oct. 28.
Researchers have discovered birth defects in rats and rabbits used to test Aubagio’s toxicity. With this in mind, scientists conducting clinical trials of Aubagio urged women who were participating to use contraceptives so they didn’t become pregnant. But some did.
An initial finding of the trials was that babies born to Aubagio-treated women did not have more birth defects than other newborns. But with more results coming in, researchers decided to do an